Exciting results from ARGO trial: -Phase 2 of Sonelokimab (dual IL-17A-IL17F) nanobody in PsA. -Met primary endpoint of ACR50 at week 12 vs PBO. -62% achieved MDA -48% achieved composite of ACR 70+PASI 100 Looking forward to phase 3 results!!! Abstract #OP0096 #EULAR2025 https://t.co/1D52eG8ReS